Product CM9241GRU

Phase 3Small molecule

Product CM9241GRU is one of 58 small molecule programs targeting Benign Prostatic Hyperplasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Benign Prostatic HyperplasiaActive, not recruiting

Allergic RhinitisActive, not recruiting

Benign Prostatic HyperplasiaPhase 3

Active, not recruiting

Allergic RhinitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Comparator: Statins

Merck & Co.

Phase 3

2 2

Flonase

Teva

Phase 3

1 3

Asmanex HFA

Sumitomo Pharma America, Inc.

Phase 3

1 4

EMS Acarbose

EEMS

Phase 3

2 5

Asmanex

Novartis

Preclinical

12 6

Product CM9241GRU

AAche Laboratorios Farmaceuticos S.A.

Phase 3

1 7

HL151

HHanlim Pharm. Co., Ltd.

Phase 3

1 8

Ismigen

LLallemand Pharma AG

Phase 3

1 9

Veramyst

Singulair

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Benign Prostatic Hyperplasia

NCT07270432

Clinical

Trials by Indication[1]

Benign Prostatic Hyperplasia1 trial

Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia

Not yet recruiting·AAche Laboratorios Farmaceuticos S.A.·Phase 3·NCT07270432·218 enrolled

Allergic Rhinitis1 trial

Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis

Not yet recruiting·AAche Laboratorios Farmaceuticos S.A.·Phase 3·NCT06577077·432 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Product CM9241GRU. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Product CM9241GRU compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Product CM9241GRU. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ache Laboratorios Farmaceuticos S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAche Laboratorios Farmaceuticos S.A.

Product CM9241GRU

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Benign Prostatic Hyperplasia1 trial

Allergic Rhinitis1 trial

References

Drug Info

Quick Facts

Related News